GLP-1r agonist pharmaceutical composition and use thereof
A pharmaceutical composition with small-molecule GLP-1 receptor agonists, enhanced by acid-resistant compounds and excipients, addresses the issues of poor oral bioavailability and compliance in peptidic agents, offering improved oral delivery and manufacturing efficiency.
AU2025207498A1Pending Publication Date: 2026-07-09JIANGSU HENGRUI MEDICINE CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- JIANGSU HENGRUI MEDICINE CO LTD
- Filing Date
- 2025-01-09
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Existing peptidic GLP-1 receptor agonists suffer from poor oral bioavailability and unsatisfactory patient compliance due to parenteral administration, necessitating the development of small-molecule GLP-1 receptor agonists with favorable oral bioavailability.
Method used
A pharmaceutical composition comprising a compound represented by formula I or its pharmaceutically acceptable salt, optionally with an acid-resistant compound and excipients like fillers, disintegrants, and lubricants, to enhance oral bioavailability and improve manufacturing processes.
Benefits of technology
The composition provides improved oral bioavailability and manufacturing efficiency of small-molecule GLP-1 receptor agonists, addressing the limitations of peptidic agents.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed are a GLP-1R agonist pharmaceutical composition and a use thereof. The pharmaceutical composition comprises a compound represented by formula I, or a pharmaceutically acceptable salt thereof, as an active ingredient. The pharmaceutical composition contains an acid-resistant compound, and can slowly release active ingredients in the pharmaceutical composition, so as to reduce side effects of in vivo absorption after GLP-1R administration.
Need to check novelty before this filing date? Find Prior Art